Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$4.19
$4.08
$1.75
$4.50
$350.97M1.181.29 million shs3.21 million shs
Erasca, Inc. stock logo
ERAS
Erasca
$1.08
-11.5%
$1.30
$1.01
$3.45
$305.95M1.121.75 million shs1.96 million shs
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$6.35
-1.4%
$4.16
$2.32
$10.13
$342.77M2.29970,476 shs492,934 shs
Immunic, Inc. stock logo
IMUX
Immunic
$0.89
-3.0%
$1.03
$0.83
$2.11
$85.28M1.73719,380 shs820,178 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.00%+0.72%+2.20%+50.72%+127.72%
Erasca, Inc. stock logo
ERAS
Erasca
-11.48%-15.63%-22.30%-22.30%-58.94%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-1.40%-2.46%+79.89%+91.27%-11.93%
Immunic, Inc. stock logo
IMUX
Immunic
-3.01%-8.59%-19.82%-23.93%-28.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.3171 of 5 stars
1.24.00.04.22.70.80.0
Erasca, Inc. stock logo
ERAS
Erasca
3.7567 of 5 stars
4.52.00.00.03.52.51.3
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
0.5988 of 5 stars
1.22.00.00.02.82.50.0
Immunic, Inc. stock logo
IMUX
Immunic
2.5053 of 5 stars
3.63.00.00.03.10.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.33
Hold$4.333.42% Upside
Erasca, Inc. stock logo
ERAS
Erasca
3.00
Buy$4.57323.28% Upside
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
2.43
Hold$5.83-8.14% Downside
Immunic, Inc. stock logo
IMUX
Immunic
3.25
Buy$13.001,360.67% Upside

Current Analyst Ratings Breakdown

Latest IMUX, CKPT, FULC, and ERAS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/23/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00 ➝ $12.00
5/23/2025
Immunic, Inc. stock logo
IMUX
Immunic
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $5.00
5/16/2025
Immunic, Inc. stock logo
IMUX
Immunic
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/15/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$10.00
5/14/2025
Erasca, Inc. stock logo
ERAS
Erasca
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$3.00
5/1/2025
Immunic, Inc. stock logo
IMUX
Immunic
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/30/2025
Erasca, Inc. stock logo
ERAS
Erasca
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
4/30/2025
Immunic, Inc. stock logo
IMUX
Immunic
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/16/2025
Immunic, Inc. stock logo
IMUX
Immunic
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
4/15/2025
Immunic, Inc. stock logo
IMUX
Immunic
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$41K8,560.27N/AN/A($0.47) per share-8.91
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/A$2.10 per shareN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$80M4.28N/AN/A$3.80 per share1.67
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/A$0.64 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$51.85M-$1.29N/AN/AN/AN/A-659.07%8/11/2025 (Estimated)
Erasca, Inc. stock logo
ERAS
Erasca
-$125.04M-$0.62N/AN/AN/AN/A-42.26%-34.97%8/11/2025 (Estimated)
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$97.33M-$0.07N/AN/AN/AN/A-7.31%-6.74%7/30/2025 (Estimated)
Immunic, Inc. stock logo
IMUX
Immunic
-$93.61M-$1.23N/AN/AN/AN/A-169.55%-118.96%8/14/2025 (Estimated)

Latest IMUX, CKPT, FULC, and ERAS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Immunic, Inc. stock logo
IMUX
Immunic
-$0.25-$0.25N/A-$0.25N/AN/A
5/13/2025Q1 2025
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A
5/13/2025Q1 2025
Erasca, Inc. stock logo
ERAS
Erasca
-$0.12-$0.11+$0.01-$0.11N/AN/A
5/1/2025Q1 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.29-$0.28+$0.01-$0.28N/AN/A
3/28/2025Q4 2024
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.22-$0.69-$0.47-$0.69N/A$0.04 million
3/20/2025Q4 2024
Erasca, Inc. stock logo
ERAS
Erasca
-$0.12-$0.11+$0.01-$0.11N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/AN/AN/AN/AN/A
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/A
0.29
0.29
Erasca, Inc. stock logo
ERAS
Erasca
N/A
11.00
11.00
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
18.44
18.44
Immunic, Inc. stock logo
IMUX
Immunic
N/A
2.71
2.71

Institutional Ownership

CompanyInstitutional Ownership
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
22.00%
Erasca, Inc. stock logo
ERAS
Erasca
67.78%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%
Immunic, Inc. stock logo
IMUX
Immunic
51.82%

Insider Ownership

CompanyInsider Ownership
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.10%
Erasca, Inc. stock logo
ERAS
Erasca
14.40%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7.00%
Immunic, Inc. stock logo
IMUX
Immunic
3.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
1083.76 million47.81 millionOptionable
Erasca, Inc. stock logo
ERAS
Erasca
120283.29 million221.94 millionOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
10053.98 million51.73 millionOptionable
Immunic, Inc. stock logo
IMUX
Immunic
7095.82 million87.38 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Checkpoint Therapeutics stock logo

Checkpoint Therapeutics NASDAQ:CKPT

$4.19 0.00 (0.00%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.18 -0.01 (-0.21%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Erasca stock logo

Erasca NASDAQ:ERAS

$1.08 -0.14 (-11.48%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.11 +0.03 (+3.15%)
As of 05/27/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$6.35 -0.09 (-1.40%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$6.35 0.00 (0.00%)
As of 05/27/2025 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Immunic stock logo

Immunic NASDAQ:IMUX

$0.89 -0.03 (-3.01%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.91 +0.02 (+2.70%)
As of 05:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.